1. Home
  2. OCSL vs GHRS Comparison

OCSL vs GHRS Comparison

Compare OCSL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$11.75

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$22.47

Market Cap

947.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCSL
GHRS
Founded
2007
2018
Country
United States
Ireland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
947.2M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
OCSL
GHRS
Price
$11.75
$22.47
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$12.63
$41.38
AVG Volume (30 Days)
757.4K
193.7K
Earning Date
05-05-2026
05-01-2026
Dividend Yield
12.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.63
$10.96
52 Week High
$14.77
$24.66

Technical Indicators

Market Signals
Indicator
OCSL
GHRS
Relative Strength Index (RSI) 39.96 61.36
Support Level $10.88 $12.65
Resistance Level $13.19 $22.88
Average True Range (ATR) 0.28 1.49
MACD -0.08 -0.13
Stochastic Oscillator 11.89 58.59

Price Performance

Historical Comparison
OCSL
GHRS

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: